Status:
UNKNOWN
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)
Lead Sponsor:
Instituto Nacional de Cardiologia Ignacio Chavez
Collaborating Sponsors:
Salvador López Gil
Armando Vázquez Rangel
Conditions:
Contrast-induced Nephropathy
Contrast-induced Acute Kidney Injury
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)
Detailed Description
Eligible patients (patients with glomerular filtration rate \< 60 ml/min or high riks patients based on Mehran score) that will be undergoing cardiac catheterization/intervention randomly assigned to ...
Eligibility Criteria
Inclusion
- Age 18 years and older who are scheduled to coronary intervention
- Patients with Mehran score \> 5 or modified Mehran score \>2 even glomerular filtration rate \> 60 ml/min (high risk patients)
- Glomerular Filtration Rate \< 60 ml/min
- All the patients provided written informed consent for the procedures and the test drug
Exclusion
- Patients with shorter hospital stay (\<48 hours)
- Patients under treatment with allopurinol of febuxostat
- Patients on renal replacement therapy
- Known allergy to allopurinol or febuxostat
Key Trial Info
Start Date :
December 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
558 Patients enrolled
Trial Details
Trial ID
NCT03767322
Start Date
December 5 2018
End Date
December 1 2019
Last Update
December 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, México City, Mexico